Catalyst Funds Management’s Royalty Pharma RPRX Stock Holding History

Catalyst Funds Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.48M	Buy	79,910 +763	+1%	+$39.7K	0.25%	109
2026 Q1	$3.8M	Hold	79,147	–	–	0.64%	33
2025 Q4	$3.06M	Hold	79,147	–	–	0.71%	26
2025 Q3	$2.79M	Buy	79,147 +47,837	+153%	+$1.73M	0.42%	49
2025 Q2	$1.13M	Sell	31,310 -34,970	-53%	-$1.16M	0.31%	100
2025 Q1	$2.06M	Buy	+66,280	New	+$2.1M	0.54%	50

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Funds Management's RPRX Position: Q2 2026 in Review

Catalyst Funds Management increased its Royalty Pharma (RPRX) stake by 0.96% in Q2 2026, buying an estimated $39.7K and bringing the position to 79,910 shares worth $4.48M. The position accounts for 0.25% of the portfolio, ranked #109.

Catalyst Funds Management first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Catalyst Funds Management held 79,910 shares of Royalty Pharma worth $4.48M as of Q2 2026.
Catalyst Funds Management bought 763 Royalty Pharma shares in Q2 2026, an estimated $39.7K.
Royalty Pharma made up 0.25% of Catalyst Funds Management's portfolio in Q2 2026, its #109 holding.
Catalyst Funds Management first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.